US2207990A - Composite barbituric-acid - Google Patents
Composite barbituric-acid Download PDFInfo
- Publication number
- US2207990A US2207990A US2207990DA US2207990A US 2207990 A US2207990 A US 2207990A US 2207990D A US2207990D A US 2207990DA US 2207990 A US2207990 A US 2207990A
- Authority
- US
- United States
- Prior art keywords
- barbiturate
- sodium
- barbituric
- carbinyl
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
Definitions
- barbituric-acid derivatives are known sedatives and hypnotics. But in general those which are available from other standpoints have a fairly low and fairly constant ratio between the duration of the hypnotic effect and the time of onsetfor those which start their action quickly also end it quickly, and those which continue their action for a long time are slow in starting that action. In consequence, they do not give both an early-starting and a long-continuing effect.
- sodium isoamyl ethyl barbiturate, orally administered ordinarily takes from thirty to forty minutes to become effective, but its effect usually continues for, perhaps six to ten hours; While sodium propyl-methyl-carbinyl ethyl barbiturate, (also called sodium ethyl (l-methylbutyl) barbiturate) similarly orally administered, ordinarily takes effect within twenty to thirty minutes but usually ceases its action within about five to seven hours, and sodium propylmethyl-carbinyl allyl barbiturate ordinarily takes effect in ten to twenty minutes but its effect usually passes off within about three to live hours. None of them, individually, gives both prompt and long-continued effect.
- the proportion between thev amounts used of the several barbituric-acid derivatives may vary as desired, in accord with the type of total efiect to be produced. For example, excellent results may be obtained by the following composite products, in terms of the usual adult oral dose.
- the corresponding barbituric acids, or other salts than the sodium salts may be used instead of the sodium salts if desired.
- the composite products obtained can be administered either orally or parenterally, in the usual manner of barbituric derivatives; although for parenteral administration the salts and not the acids are desirable. Oral administration is usually preferred for human use.
- My composite barbituric-acid derivatives are found especially advantageous in obstetrics, in pre-surgical anesthesia, and as hypnotics for general use.
- a composite barbituric-acid derivative suitable for oral and parenteral administration comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl allyl barbiturate.
- a composite barbituric-acid derivative suitable for oral and parenteral administration comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
- a composite barbituric-acid derivative suitable for oral and parenteral administration comprising sodium propyl-methyl-carbinyl allyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
- a composite barbituric-acid derivative suitable for oral and parenteral administration comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl allyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
Description
Patented July 16, 1940 COMPOSITE BARBITURIC-ACID DERIVATIVE Charles R. Miller, Indianapolis, Ind., assignor to Eli Lilly and Company, Indianapolis, Ind., a
corporation of Indiana No Drawing. Application'June 24, 1938,
Serial No. 215,583
4 Claims.
It is the object of my invention to produce a barbituric sedative and hypnotic which both acts promptly and exerts a fairly uniform effect over a considerable period.
Many barbituric-acid derivatives are known sedatives and hypnotics. But in general those which are available from other standpoints have a fairly low and fairly constant ratio between the duration of the hypnotic effect and the time of onsetfor those which start their action quickly also end it quickly, and those which continue their action for a long time are slow in starting that action. In consequence, they do not give both an early-starting and a long-continuing effect.
I have discovered that by putting together two or more barbituric-acid derivatives which have different times of onset and different durations of action I am able to get both early starting and long duration; and, most surprisingly, that the onset of action may be made to be even quicker than that of the quick-acting barbituric-acid derivative and/or that the duration of action may be made to be even greater than that of the slow-acting barbituric-acid derivative.
Thus, sodium isoamyl ethyl barbiturate, orally administered, ordinarily takes from thirty to forty minutes to become effective, but its effect usually continues for, perhaps six to ten hours; While sodium propyl-methyl-carbinyl ethyl barbiturate, (also called sodium ethyl (l-methylbutyl) barbiturate) similarly orally administered, ordinarily takes effect within twenty to thirty minutes but usually ceases its action within about five to seven hours, and sodium propylmethyl-carbinyl allyl barbiturate ordinarily takes effect in ten to twenty minutes but its effect usually passes off within about three to live hours. None of them, individually, gives both prompt and long-continued effect.
But by putting together one of these three types of barbituric-acid derivatives with either or both of the others, it becomes possible to increase the ratio between the duration of action and the time of onset.
The proportion between thev amounts used of the several barbituric-acid derivatives may vary as desired, in accord with the type of total efiect to be produced. For example, excellent results may be obtained by the following composite products, in terms of the usual adult oral dose.
Example 1:
Sodium isoamylv ethyl barbiturate 1 grains Sodium propyl-methyfl-carbinyl allyl barbiturate 1% grains Example 2:
Sodium isoamyl ethyl barbiturate" 2 grains Sodium propyl-methyl-carbinyl al-' lyl barbiturate 1 grain Example 3:
Sodium isoamyl ethyl barbiturate 1 Sodium propyl-methyl-carbinyl allyl barbiturate 2 Example 4:
Sodium isoamyl ethyl barbiturate 1 Sodium propyl-methyll-carbinyl ethyl barbiturate 1 /2 grain grains 15 grains 20 grains Example 5:
Sodium isoamyl ethyl barbiturate 2 Sodium propyl methyl carbinyl ethyl barbiturate 1 Example 6:
Sodium isoamyl ethyl barbiturate 1 Sodium propyl methyl carbinyl ethyl barbiturate 2 Example 7:
Sodium propyl-methyil-carbinyl ethyl barbiturate 1 Sodium propyl-methyfl-carbinyl allyl barbiturate 1 Example 8:
Sodium isoamyl ethyl barbiturate 1% Sodium propyl-methyfl-carbinyl ethyl barbiturate Sodium propyl-methy'l-carbinyl allyl barbiturate grains grain grain grains 30 grains grains grains 40 grain grain Example 10:
Sodium di-ethyl barbiturate 2 grains Sodium isoamyl ethyl barbiturate 1 grain Sodium propyl-methyl-carbinyl al- In these examples, the corresponding barbituric acids, or other salts than the sodium salts, may be used instead of the sodium salts if desired.
The composite products obtained can be administered either orally or parenterally, in the usual manner of barbituric derivatives; although for parenteral administration the salts and not the acids are desirable. Oral administration is usually preferred for human use.
My composite barbituric-acid derivatives are found especially advantageous in obstetrics, in pre-surgical anesthesia, and as hypnotics for general use.
I- claim as my invention:
1. A composite barbituric-acid derivative suitable for oral and parenteral administration, comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl allyl barbiturate.
2. A composite barbituric-acid derivative suitable for oral and parenteral administration, comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
3. A composite barbituric-acid derivative suitable for oral and parenteral administration, comprising sodium propyl-methyl-carbinyl allyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
4. A composite barbituric-acid derivative suitable for oral and parenteral administration, comprising sodium isoamyl ethyl barbiturate and sodium propyl-methyl-carbinyl allyl barbiturate and sodium propyl-methyl-carbinyl ethyl barbiturate.
CHARLES R. MILLER.
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2207990A true US2207990A (en) | 1940-07-16 |
Family
ID=3431356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US2207990D Expired - Lifetime US2207990A (en) | Composite barbituric-acid |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2207990A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2603583A (en) * | 1949-03-04 | 1952-07-15 | Welch Henry | Pectin penicillin preparation |
| US2619447A (en) * | 1949-03-11 | 1952-11-25 | American Cyanamid Co | Injectable penicillin preparations |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
| US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2824546A (en) * | 1950-10-20 | 1958-02-25 | Klette Hermann | Treating animals with hormone preparation |
-
0
- US US2207990D patent/US2207990A/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2603583A (en) * | 1949-03-04 | 1952-07-15 | Welch Henry | Pectin penicillin preparation |
| US2619447A (en) * | 1949-03-11 | 1952-11-25 | American Cyanamid Co | Injectable penicillin preparations |
| US2824546A (en) * | 1950-10-20 | 1958-02-25 | Klette Hermann | Treating animals with hormone preparation |
| US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clark et al. | Cutting edge: Cytokine-dependent abortion in CBA× DBA/2 mice is mediated by the procoagulant fgl2 prothombinase | |
| Mantovani et al. | Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy | |
| La Flamme et al. | Role of IL-6 in directing the initial immune response to schistosome eggs | |
| JP6963545B2 (en) | Combination therapy to treat cancer | |
| Furukawa et al. | IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos | |
| US2207990A (en) | Composite barbituric-acid | |
| JP2022116304A (en) | PPAR-γ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| Zhu et al. | Thyroxine affects lipopolysaccharide-induced macrophage differentiation and myocardial cell apoptosis via the NF-κB p65 pathway both in vitro and in vivo | |
| Eden et al. | Interleukin-1 secretion by human alveolar macrophages stimulated with endotoxin is augmented by recombinant immune (gamma) interferon | |
| JP4854198B2 (en) | Combination of nitrogen mustard analog and imatinib for the treatment of chronic lymphocytic leukemia | |
| Fisher et al. | Anastrozole-induced subacute cutaneous lupus erythematosus | |
| JP2016128437A (en) | Combination of hdac inhibitors with thrombocytopenia drugs | |
| BR112020005039A2 (en) | combination of a btk inhibitor and a cdk9 inhibitor to treat cancer | |
| Antopol et al. | Blood amylase response to acetylcholine and its modification by physostigmine and atropine | |
| BRPI0611092A2 (en) | pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome | |
| JPH08501069A (en) | Treatment of pathological hypotension by combined use of cardiotonics and nitric oxide synthesis inhibitors | |
| Kuehn et al. | Prior and concomitant dehydroepiandrosterone treatment affects immunologic response of cultured macrophages infected with Trypanosoma cruzi in vitro? | |
| KR20090125246A (en) | Agent for prevention and/or treatment of systemic lupus erythematosus | |
| Xu et al. | Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance | |
| JP2007509932A5 (en) | ||
| BR112020021896A2 (en) | METHODS AND COMPOSITIONS TO REDUCE THE RISK OF RECURRENCE AND PROLONG THE SURVIVAL IN ACUTE MYELOID LEUKEMIA | |
| US3090726A (en) | Novel composition of matter for treatment of nervous disorders | |
| Adam et al. | P148 JAK-inhibition by baricitinib and tofacitinib ameliorates pathological bone loss | |
| US2922743A (en) | Amebicidal compositions | |
| WO2023097071A3 (en) | Methods for treating traumatic brain injury |